Fortress Biotech, Inc. 8-K

What Happened
Fortress Biotech, Inc. announced on March 31, 2026 that it issued a press release providing a corporate update and reporting its financial results for the year ended December 31, 2025. The press release is furnished as Exhibit 99.1 to the company's Form 8-K. The filing notes that the information (including the press release) is being furnished and is not being “filed” for purposes of Section 18 of the Securities Exchange Act.

Key Details

• Item reported: 2.02 Results of Operations and Financial Condition — press release announcing 2025 year‑end results.
• Filing date: March 31, 2026; reporting period covered: year ended December 31, 2025.
• Exhibit furnished: Exhibit 99.1 (press release).
• Signature: Form 8-K executed by David Jin, Chief Financial Officer of Fortress Biotech.
• The company clarifies the exhibit is furnished (not filed) and will not be automatically incorporated by reference into other SEC filings unless expressly stated.

Why It Matters
This 8-K signals that Fortress has released its full-year 2025 results and a corporate update—information investors often use to assess recent performance (earnings, revenue, cash position, pipeline progress). Because the filing furnishes a press release rather than filing it, the company limits certain legal liabilities tied to SEC “filed” disclosures. Investors should read the Exhibit 99.1 press release and the company’s subsequent filings (e.g., Form 10-K) for complete financial details and metrics before making investment decisions.